目的探讨MR影像组学模型鉴别HER2低表达与HER2阳性乳腺癌的应用价值。方法回顾性分析我院2018年1月至12月确诊的浸润性乳腺癌233例,其中HER2阳性乳腺癌103例,HER2低表达乳腺癌130例,按8:2随机拆分为训练集186例及测试集47例。基于MR第2...目的探讨MR影像组学模型鉴别HER2低表达与HER2阳性乳腺癌的应用价值。方法回顾性分析我院2018年1月至12月确诊的浸润性乳腺癌233例,其中HER2阳性乳腺癌103例,HER2低表达乳腺癌130例,按8:2随机拆分为训练集186例及测试集47例。基于MR第2期增强图像提取组学特征,数据经过归一化,降维,筛选特征,构建逻辑回归机器学习模型,并于测试集中验证及评估其诊断效能。结果训练集中AUC为0.87,准确率为0.80,敏感性0.89,特异性0.72,PPV0.72,NPV0.89,测试集中AUC值为0.77,准确率0.77,敏感度0.76,特异性0.77,PPV0.73,NPV0.80,基于DCE-MR影像组学的预测模型不仅具有较好的诊断效能,还具有良好的稳定性。结论基于DCE-MR影像组学预测模型鉴别HE R2低表达与H E R2阳性乳腺癌具有较好的诊断效能,有望为后期临床制定精准化及个性化治疗决策提供参考依据。展开更多
Objective This study aimed to comprehensively analyze and compare the clinicopathological features and prognosis of Chinese patients with human epidermal growth factor receptor 2(HER2)-low early breast cancer(BC)and H...Objective This study aimed to comprehensively analyze and compare the clinicopathological features and prognosis of Chinese patients with human epidermal growth factor receptor 2(HER2)-low early breast cancer(BC)and HER2-IHC0 BC.Methods Patients diagnosed with HER2-negative BC(N=999)at our institution between January2011 and December 2015 formed our study population.Clinicopathological characteristics,association between estrogen receptor(ER)expression and HER2-low,and evolution of HER2 immunohistochemical(IHC)score were assessed.Kaplan-Meier method and log-rank test were used to compare the long-term survival outcomes(5-year follow-up)between the HER2-IHC0 and HER2-low groups.Results HER2-low BC group tended to demonstrate high expression of ER and more progesterone receptor(PgR)positivity than HER2-IHC0 BC group(P<0.001).The rate of HER2-low status increased with increasing ER expression levels(Mantel-Haenszelχ^(2)test,P<0.001,Pearson’s R=0.159,P<0.001).Survival analysis revealed a significantly longer overall survival(OS)in HER2-low BC group than in HER2-IHC0 group(P=0.007)in the whole cohort and the hormone receptor(HR)-negative group.There were no significant differences between the two groups in terms of disease-free survival(DFS).The discordance rate of HER2 IHC scores between primary and metastatic sites was 36.84%.Conclusion HER2-low BC may not be regarded as a unique BC group in this population-based study due to similar clinicopathological features and prognostic roles.展开更多
文摘目的探讨MR影像组学模型鉴别HER2低表达与HER2阳性乳腺癌的应用价值。方法回顾性分析我院2018年1月至12月确诊的浸润性乳腺癌233例,其中HER2阳性乳腺癌103例,HER2低表达乳腺癌130例,按8:2随机拆分为训练集186例及测试集47例。基于MR第2期增强图像提取组学特征,数据经过归一化,降维,筛选特征,构建逻辑回归机器学习模型,并于测试集中验证及评估其诊断效能。结果训练集中AUC为0.87,准确率为0.80,敏感性0.89,特异性0.72,PPV0.72,NPV0.89,测试集中AUC值为0.77,准确率0.77,敏感度0.76,特异性0.77,PPV0.73,NPV0.80,基于DCE-MR影像组学的预测模型不仅具有较好的诊断效能,还具有良好的稳定性。结论基于DCE-MR影像组学预测模型鉴别HE R2低表达与H E R2阳性乳腺癌具有较好的诊断效能,有望为后期临床制定精准化及个性化治疗决策提供参考依据。
基金supported by grants from the Health Care Special Project,Grant/Award Number:17BJZ40。
文摘Objective This study aimed to comprehensively analyze and compare the clinicopathological features and prognosis of Chinese patients with human epidermal growth factor receptor 2(HER2)-low early breast cancer(BC)and HER2-IHC0 BC.Methods Patients diagnosed with HER2-negative BC(N=999)at our institution between January2011 and December 2015 formed our study population.Clinicopathological characteristics,association between estrogen receptor(ER)expression and HER2-low,and evolution of HER2 immunohistochemical(IHC)score were assessed.Kaplan-Meier method and log-rank test were used to compare the long-term survival outcomes(5-year follow-up)between the HER2-IHC0 and HER2-low groups.Results HER2-low BC group tended to demonstrate high expression of ER and more progesterone receptor(PgR)positivity than HER2-IHC0 BC group(P<0.001).The rate of HER2-low status increased with increasing ER expression levels(Mantel-Haenszelχ^(2)test,P<0.001,Pearson’s R=0.159,P<0.001).Survival analysis revealed a significantly longer overall survival(OS)in HER2-low BC group than in HER2-IHC0 group(P=0.007)in the whole cohort and the hormone receptor(HR)-negative group.There were no significant differences between the two groups in terms of disease-free survival(DFS).The discordance rate of HER2 IHC scores between primary and metastatic sites was 36.84%.Conclusion HER2-low BC may not be regarded as a unique BC group in this population-based study due to similar clinicopathological features and prognostic roles.
